成人用ワクチン市場：ワクチンタイプ、適応疾患、エンドユーザー別-2025～2030年の世界予測

成人用ワクチン市場の2023年の市場規模は176億3,000万米ドルで、2024年には191億1,000万米ドルに達すると予測され、CAGR 8.28％で成長し、2030年には307億8,000万米ドルに達すると予測されています。

成人用ワクチン市場には、成人の感染症予防を目的としたワクチンの市場開拓、生産、応用が含まれます。同市場は、世界人口の高齢化、予防可能な疾患に対する意識の高まり、政府による予防接種の取り組みなどの要因により、ワクチン接種の必要性が高まっていることに対応しています。適用範囲には、インフルエンザ、髄膜炎、HPV、肝炎に対するワクチンが含まれ、最終用途は個人の健康維持から公衆衛生プログラムまで多岐にわたります。成長に影響を与える主要要因としては、医療政策に対する政府の関心の高まり、ワクチン技術の進歩、疾病予防に対する国民の意識の高まりなどが挙げられます。ワクチン接種率が低い新興市場には成長機会が多く、医療へのアクセス向上が成長の原動力となります。業界各社は、アウトリーチや教育を拡大するために、医療プロバイダーや公衆衛生機関との連携に注力すべきです。しかし、ワクチン接種のためらい、規制上のハードル、流通ロジスティックスなどの課題は、市場拡大を制限する可能性があります。さらに、高い研究開発コストと時間のかかる承認プロセスが大きな課題となっています。これらを克服するためには、針を使わないシステムなどの革新的な送達技術への投資や混合ワクチンの研究が、潜在的な成長手段となりうる。さらに、個々の免疫系の変化に対応する個別化ワクチンは、市場に革命をもたらす可能性があります。成人用ワクチン市場の性質はダイナミックであり、生物医療の絶え間ない進歩と進化する世界の健康需要に後押しされています。サステイナブル事業成長のためには、利害関係者は強力な研究開発に取り組み、より効果的な流通チャンネルのためのパートナーシップを育み、変動する社会のニーズや規制状況に対応するための適応戦略を実施すべきです。ワクチンの入手しやすさと効率性の向上に注力し、迅速なワクチン開発と流通を促進する技術に投資することで、市場は課題を克服し、成長機会を得ることができます。

市場力学：急速に進化する成人用ワクチン市場の主要市場洞察を公開

成人用ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また消費者行動とそれが製造コストや購買傾向に与える影響についてもより明確に理解することができます。

ポーターの5つの力：成人用ワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：成人用ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、成人用ワクチン市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析成人用ワクチン市場における競合情勢の把握

成人用ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス成人用ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、成人用ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨成人用ワクチン市場における成功への道筋を描く

成人用ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した包括的な市場分析を提供しています。

1.市場の浸透度：現在の市場環境についての詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存セクターにおける拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを調査します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行えるよう、重要な質問にも回答しています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 医療インフラの拡大とワクチン接種サービスへのアクセス
    • 個人や地域社会における予防医療の重要性の高まり
    • ワクチンで予防可能な新たな疾患や変異体の出現
  • 抑制要因
    • ワクチンの開発と流通に伴う高コストが市場への到達を制限
  • 機会
    • 旅行業界の利害関係者と協力し、旅行ワクチンを推進し、旅行者の健康を確保
    • ワクチン接種率を高めるために高齢者層を対象とした包括的な予防接種プログラム
  • 課題
    • 厳しい政府規制と長期にわたる承認プロセスがワクチン市場の拡大を妨げている
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 成人用ワクチン市場：ワクチンタイプ別

• イントロダクション
• 不活化ワクチン
  • ウイルスワクチンの分割
  • 全ウイルスワクチン
• 生弱毒化ワクチン
• サブユニットワクチン
  • 多糖類ワクチン
  • タンパク質サブユニットワクチン
• トキソイドワクチン

第7章 成人用ワクチン市場：適応疾患別

• イントロダクション
• B型肝炎
• 帯状疱疹
• ヒトパピローマウイルス（HPV）
• インフルエンザ
• 肺炎球菌感染症

第8章 成人用ワクチン市場：エンドユーザー別

• イントロダクション
• クリニック
• 在宅医療
• 病院
• ワクチン接種センター

第9章 南北アメリカの成人用ワクチン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の成人用ワクチン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの成人用ワクチン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. AstraZeneca
• 2. Bharat Biotech
• 3. BioNTech
• 4. CSL Limited
• 5. CureVac
• 6. Dynavax Technologies
• 7. Emergent BioSolutions
• 8. GlaxoSmithKline
• 9. Inovio Pharmaceuticals
• 10. Johnson & Johnson
• 11. Merck & Co.
• 12. Moderna
• 13. Novavax
• 14. Pfizer
• 15. Sanofi
• 16. Seqirus
• 17. Serum Institute of India
• 18. Sinovac Biotech
• 19. Valneva SE
• 20. Vaxart

LIST OF FIGURES

• FIGURE 1. ADULT VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. ADULT VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ADULT VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ADULT VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY SPLIT VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ADULT VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ADULT VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ADULT VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ADULT VACCINES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. CANADA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. CHINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 74. CHINA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 75. CHINA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. INDIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 79. INDIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 80. INDIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. ITALY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 165. ITALY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 166. ITALY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. POLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 185. POLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 186. POLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. QATAR ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 190. QATAR ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 191. QATAR ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 238. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 239. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

The Adult Vaccines Market was valued at USD 17.63 billion in 2023, expected to reach USD 19.11 billion in 2024, and is projected to grow at a CAGR of 8.28%, to USD 30.78 billion by 2030.

The adult vaccines market encompasses the development, production, and application of vaccines aimed at preventing infectious diseases in adults. This market addresses the increasing necessity for vaccination due to factors such as the aging global population, rising awareness about preventable diseases, and governmental immunization initiatives. The application scope includes vaccines against influenza, meningitis, HPV, and hepatitis, with end-uses ranging from individual health maintenance to public health programs. Key factors influencing growth include heightened governmental focus on healthcare policies, advances in vaccine technology, and the public's growing awareness of disease prevention. Opportunities abound in emerging markets with low vaccination coverage, where increasing healthcare access can drive growth. Industry players should focus on collaboration with healthcare providers and public health organizations to expand outreach and education. However, challenges such as vaccine hesitancy, regulatory hurdles, and distribution logistics can limit market expansion. Furthermore, high R&D costs and time-consuming approval processes pose significant challenges. To overcome these, investment in innovative delivery technologies, such as needle-free systems, and research into combination vaccines can offer potential growth avenues. Additionally, personalized vaccines that cater to individual immune system variations could revolutionize the market. The nature of the adult vaccine market is dynamic, driven by constant advancements in biomedical science and evolving global health demands. For sustainable business growth, stakeholders should engage in robust R&D, foster partnerships for more effective distribution channels, and implement adaptive strategies to address fluctuating societal needs and regulatory landscapes. By focusing on improving vaccine accessibility and efficiency, and investing in technologies that facilitate rapid vaccine development and distribution, the market can navigate its challenges and harness opportunities for growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adult Vaccines Market

The Adult Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Expansion of healthcare infrastructure and access to vaccination services
  • Growing emphasis on preventive healthcare among individuals and communities
  • Emergence of new vaccine-preventable diseases and variants
• Market Restraints
  • High costs associated with vaccine development and distribution limit market reach
• Market Opportunities
  • Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
  • Comprehensive immunization programs targeting the aging population to increase vaccine uptake
• Market Challenges
  • Stringent government regulations and lengthy approval processes hinder vaccine market expansion

Porter's Five Forces: A Strategic Tool for Navigating the Adult Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adult Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adult Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adult Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adult Vaccines Market

A detailed market share analysis in the Adult Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adult Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adult Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adult Vaccines Market

A strategic analysis of the Adult Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adult Vaccines Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, BioNTech, CSL Limited, CureVac, Dynavax Technologies, Emergent BioSolutions, GlaxoSmithKline, Inovio Pharmaceuticals, Johnson & Johnson, Merck & Co., Moderna, Novavax, Pfizer, Sanofi, Seqirus, Serum Institute of India, Sinovac Biotech, Valneva SE, and Vaxart.

Market Segmentation & Coverage

This research report categorizes the Adult Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Vaccine Type, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, and Toxoid Vaccines. The Inactivated Vaccines is further studied across Split Virus Vaccines and Whole Virus Vaccines. The Subunit Vaccines is further studied across Polysaccharide Vaccines and Protein Subunit Vaccines.
• Based on Disease Indication, market is studied across Hepatitis B, Herpes Zoster, Human Papillomavirus (HPV), Influenza, and Pneumococcal Disease.
• Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Vaccination Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Expansion of healthcare infrastructure and access to vaccination services
    • 5.1.1.2. Growing emphasis on preventive healthcare among individuals and communities
    • 5.1.1.3. Emergence of new vaccine-preventable diseases and variants
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with vaccine development and distribution limit market reach
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
    • 5.1.3.2. Comprehensive immunization programs targeting the aging population to increase vaccine uptake
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations and lengthy approval processes hinder vaccine market expansion
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Adult Vaccines Market, by Vaccine Type

• 6.1. Introduction
• 6.2. Inactivated Vaccines
  • 6.2.1. Split Virus Vaccines
  • 6.2.2. Whole Virus Vaccines
• 6.3. Live Attenuated Vaccines
• 6.4. Subunit Vaccines
  • 6.4.1. Polysaccharide Vaccines
  • 6.4.2. Protein Subunit Vaccines
• 6.5. Toxoid Vaccines

7. Adult Vaccines Market, by Disease Indication

• 7.1. Introduction
• 7.2. Hepatitis B
• 7.3. Herpes Zoster
• 7.4. Human Papillomavirus (HPV)
• 7.5. Influenza
• 7.6. Pneumococcal Disease

8. Adult Vaccines Market, by End User

• 8.1. Introduction
• 8.2. Clinics
• 8.3. Homecare Settings
• 8.4. Hospitals
• 8.5. Vaccination Centers

9. Americas Adult Vaccines Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Adult Vaccines Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Adult Vaccines Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca
• 2. Bharat Biotech
• 3. BioNTech
• 4. CSL Limited
• 5. CureVac
• 6. Dynavax Technologies
• 7. Emergent BioSolutions
• 8. GlaxoSmithKline
• 9. Inovio Pharmaceuticals
• 10. Johnson & Johnson
• 11. Merck & Co.
• 12. Moderna
• 13. Novavax
• 14. Pfizer
• 15. Sanofi
• 16. Seqirus
• 17. Serum Institute of India
• 18. Sinovac Biotech
• 19. Valneva SE
• 20. Vaxart